- cafead   May 20, 2021 at 12:22: PM
via When Ipsen announced last week that it wanted in on Exelixis' Cabometyx for thyroid cancer, the company pegged that move to the oncology drug's promising late-stage trial results. Now, Exelixis is offering up more details of that very trial.
article source
article source